一分钟看懂
这是一项关于急性髓系白血病的I 期 / II 期研究，登记的药物或干预包括BGB-11417；Azacitidine；Posaconazole，当前状态为招募中。登记地点显示中国北京、兰州、广州、深圳等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BGB-11417；Azacitidine；Posaconazole · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University Peoples Hospital · 北京
- The First Hospital of Lanzhou University · 兰州
- Guangdong Provincial Peoples Hospital · 广州
- Nanfang Hospital, Southern Medical University · 广州
- The Second Peoples Hospital of Shenzhen · 深圳
- Henan Cancer Hospital · 郑州
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology · 武汉
- The First Affiliated Hospital of Soochow University · 苏州
- The First Affiliated Hospital of Nanchang University Branch Donghu · 南昌
- West China Hospital, Sichuan University · 成都
- Tianjin Medical University Cancer Institute and Hospital · 天津
- The First Affiliated Hospital, Zhejiang University School of Medicine · 杭州
公开的入选条件
- 1. Confirmed diagnosis of one of the following by 2016 World Health Organization criteria:
- AML, nonacute promyelocytic leukemia
- 2. Eastern Cooperative Oncology Group performance status of 0 to 2.
- 3. Adequate organ function defined as:
- Creatinine clearance ≥ 50 milliliters/minute (mL/min) (or between 30 and 49 mL/min in unfit AML cohort)
- Adequate liver function
- 4. Life expectancy of \> 12 weeks.
- 5. Ability to comply with the requirements of the study.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04771130；登记信息更新于 2026-09-14。